Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14479196 | 0.84 | GAA (0.46) | MAPTGAARAB9AMEN1KMT2A | |
| SCHEMBL1337353 | 0.83 | CA12 (0.57) | MAPTGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL6921478 | 0.81 | DAO (0.47) | MAPTGAARAB9AMEN1KMT2A | |
| SCHEMBL719505 | 0.81 | GSK3A (0.53) | MAPTGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL121145 | 0.81 | LMNA (0.63) | MAPTRAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL29421589 | 0.81 | LMNA (0.63) | MAPTRAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL7244105 | 0.81 | MAPT (0.55) | MAPTGAARAB9AMEN1KMT2A | |
| SCHEMBL9519219 | 0.76 | MAPK1 (0.48) | MAPTGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL29018590 | 0.76 | GAA (0.56) | MAPTGAARAB9AMEN1KMT2A | |
| SCHEMBL10488389 | 0.76 | RAB9A (0.53) | MAPTGAARAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1589029-B1 | Pyrazinone protease inhibitors | ORTHO MCNEIL PHARM INC (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-1086122-B1 | PYRAZINONE PROTEASE INHIBITORS | JOHNSON & JOHNSON PHARM RES (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6515129-B1 | A pharmaceutical composition which comprises, a cyclic imide derivative represented by the general formula (I): present invention relates to an aminopeptidase N inhibitor or an angiogenesis inhibitor, modulates production of tumor necrosis | ISHIHARA SANGYO KAISHA LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-6514978-B2 | Compounds such as 1-(n-(2-(amidinoaminooxy)ethyl)amino) carbonylmethyl-6-methyl-3-(phenethylamino)-pyrazinone attached to a polymer coated onto a medical device for blood collection or storage; antiagglomerants | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| US-6429212-B1 | AMINOPEPTIDASE N INHIBITOR USED TO TREAT CANCER, TUMORS, AND RETINOPATHY; FEW SIDE EFFECTS; ANGIOGENESIS INHIBITOR | ISHIHARA SANGYO KAISHA LTD. (JP) | 2002-08-06 | — | — | US | disclosed |
| US-20010021713-A1 | Thromboresistant materials incorporating pyrazinone protease inhibitors | LU TIANBAO (US) | 2001-09-13 | — | — | US | disclosed |
| US-6204263-B1 | THROMBIN INHIBITORS. | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021713-A1 | Thromboresistant materials incorporating pyrazinone protease inhibitors | HPN, SERPINE1, SERPINC1 | MAPT 3709/4885GAA 2529/4885RAB9A 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.